急性眼痛の世界市場レポート 2025年

急性眼痛市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6％で6億米ドルに成長します。この予測期間における成長は、有利な償還政策、新興市場におけるアクセスの拡大、眼疾患の有病率の増加、標的を絞った効果的な眼痛治療に対する需要の高まり、患者中心のケアへの重点化の高まりなどに起因すると考えられます。この期間の主な動向としては、診断の進歩、技術革新、新剤形、新規ドラッグデリバリー・システム、人工知能の統合などが挙げられます。

眼外傷の発生頻度の増加が急性眼痛市場の成長を牽引すると予想されます。目の傷害は、衝撃、異物への暴露、化学物質、火傷などによる眼球やその周囲の外傷や損傷によって発生します。これらの傷害は、痛みや視力障害、長期的な損傷の可能性につながります。目の傷害の発生率が増加しているのは、職場での危険の増加、長時間のスクリーン使用、環境汚染物質、スポーツに関連した外傷、目の保護が不十分であることなどが原因と考えられます。急性眼痛は眼外傷の重要な指標であり、早期の診断と介入を促します。しかし、疼痛管理が遅れたり、不十分であったりすると、合併症が悪化し、不快感が長引いたり、視力障害が生じたりする可能性があります。例えば、2024年8月、ウェールズ政府は、ウェールズの眼科の2023-24年の入院患者数が前年比5.8％増の3万5,000人を超えたと報告しました。その結果、眼外傷の発生率の増加が急性眼痛市場の治療需要を牽引しています。

急性眼痛市場の企業は、神経障害性角膜痛（NCP）療法など、重度の目の痛みに対処するための新規治療法の開発に注力しています。NCP療法は、角膜の神経損傷や機能障害に起因する慢性的でしばしば激しい眼痛を管理・緩和するためのアプローチです。例えば、2024年10月、英国に本拠を置くOKYO Pharma社は、新しい神経障害性角膜疼痛治療薬OK-101の第2相臨床試験で最初の患者を投与したと発表しました。OK-101は、非オピオイド性抗炎症治療薬であり、角膜神経の損傷と強い眼の不快感に関連するNCPに対処することを目的としています。NCPと診断された患者48名を登録する第2相臨床試験は、眼痛管理の第一人者であるPedram Hamrah医師の監督の下、タフツ医療センターで実施されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性眼痛PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性眼痛市場：成長率分析
• 世界の急性眼痛市場の実績：規模と成長, 2019-2024
• 世界の急性眼痛市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性眼痛総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性眼痛市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所非ステロイド性抗炎症薬
• 局所毛様体麻痺薬
• 経口鎮痛剤
• コルチコステロイド
• 免疫調節薬
• 世界の急性眼痛市場病状別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 角膜剥離
• 緑内障
• 結膜炎
• 虹彩炎
• その他の病状
• 世界の急性眼痛市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トピック
• 眼内
• オーラル
• その他の投与経路
• 世界の急性眼痛市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の急性眼痛市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 眼科クリニック
• その他のエンドユーザー
• 世界の急性眼痛市場、局所非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ケトロラク
• ブロムフェナク
• ネパフェナク
• ジクロフェナク
• 世界の急性眼痛市場局所毛様体麻痺薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトロピン
• シクロペントレート
• ホマトロピン
• 世界の急性眼痛市場経口鎮痛剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アセトアミノフェン
• イブプロフェン
• トラマドール
• コデイン
• 世界の急性眼痛市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾロン
• デキサメタゾン
• フルオロメトロン
• ロテプレドノール
• 世界の急性眼痛市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロスポリン
• タクロリムス
• リフィテグラスト

第7章 地域別・国別分析

• 世界の急性眼痛市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性眼痛市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性眼痛市場：競合情勢
• 急性眼痛市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Alcon Vision LLC Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bausch+Lomb Corporation
• Santen Pharmaceutical
• Dompe Farmaceutici S.p.A.
• Aldeyra Therapeutics Inc.
• Ocular Therapeutix
• Nicox S.A.
• Omeros Corporation
• Chromocell Therapeutics Corporation
• XOMA Corporation
• Vyluma
• Sylentis
• Surface Ophthalmics Inc.
• Pharmaleads
• Kala Bio
• IACTA Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性眼痛市場2029：新たな機会を提供する国
• 急性眼痛市場2029：新たな機会を提供するセグメント
• 急性眼痛市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute ocular pain is a sudden, intense discomfort or sharp sensation in the eye, often caused by infections, injuries, inflammation, or underlying medical conditions. It may be accompanied by symptoms such as redness, swelling, vision disturbances, or sensitivity to light, and requires prompt evaluation to identify the cause and determine appropriate treatment. This pain can result from conditions such as corneal abrasions, uveitis, glaucoma, or foreign body irritation and may signal a serious issue that needs urgent medical attention to avoid complications.

The main drugs used in managing acute ocular pain include topical non-steroidal anti-inflammatory drugs (NSAIDs), topical cycloplegic agents, oral analgesics, corticosteroids, and immunomodulators. Topical NSAIDs, in the form of eye drops, are used to reduce inflammation and relieve acute ocular pain by inhibiting cyclooxygenase enzymes. These drugs are categorized based on conditions such as corneal abrasion, glaucoma, conjunctivitis, and iritis, and are administered through various routes, including topical, intraocular, and oral. The distribution channels for these treatments include hospital pharmacies, online pharmacies, and retail pharmacies, with end users ranging from hospitals and home care settings to ophthalmic clinics.

The acute ocular pain market research report is one of a series of new reports from The Business Research Company that provides acute ocular pain market statistics, including acute ocular pain industry global market size, regional shares, competitors with an acute ocular pain market share, detailed acute ocular pain market segments, market trends and opportunities, and any further data you may need to thrive in the acute ocular pain industry. This acute ocular pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute ocular pain market size has grown strongly in recent years. It will grow from $0.40 billion in 2024 to $0.43 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to the rising incidence of eye injuries and ocular surgeries, growing awareness about ocular health, an aging population, rapid urbanization, and increased healthcare expenditure.

The acute ocular pain market size is expected to see strong growth in the next few years. It will grow to $0.60 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to favorable reimbursement policies, expanding access in emerging markets, the increasing prevalence of ocular ailments, rising demand for targeted and effective ocular pain therapies, and a growing emphasis on patient-centric care. Key trends during this period include advancements in diagnostics, technological innovations, new drug formulations, novel delivery systems, and the integration of artificial intelligence.

The increasing frequency of eye injuries is expected to drive the growth of the acute ocular pain market. Eye injuries can occur due to trauma or damage to the eye or its surrounding areas, resulting from impact, exposure to foreign objects, chemicals, or burns. These injuries can lead to pain, vision problems, and potential long-term damage. The growing incidence of eye injuries can be attributed to factors such as rising workplace hazards, prolonged screen time, environmental pollutants, sports-related trauma, and insufficient eye protection. Acute ocular pain is a significant indicator of underlying eye trauma, prompting early diagnosis and intervention. However, if pain management is delayed or inadequate, complications can worsen, resulting in prolonged discomfort and potential vision impairment. For instance, in August 2024, the Welsh Government reported that ophthalmology departments in Wales had more than 35,000 admissions in 2023-24, a 5.8% increase from the previous year. As a result, the increasing incidence of eye injuries is driving the demand for treatments in the acute ocular pain market.

Companies in the acute ocular pain market are focusing on the development of novel treatments, such as neuropathic corneal pain (NCP) therapy, to address severe eye pain. NCP therapy involves approaches designed to manage and alleviate chronic and often severe eye pain caused by nerve damage or dysfunction in the cornea. For example, in October 2024, UK-based OKYO Pharma announced the dosing of the first patient in its Phase 2 clinical trial for OK-101, a new neuropathic corneal pain therapy. OK-101 is a non-opioid, anti-inflammatory treatment aimed at addressing NCP, a condition linked to corneal nerve damage and intense eye discomfort. The Phase 2 trial, which will enroll 48 patients diagnosed with NCP, is being conducted at Tufts Medical Center under the supervision of Dr. Pedram Hamrah, a leading expert in ocular pain management.

In November 2022, Alcon Inc., a Switzerland-based ophthalmic company, acquired Aerie Pharmaceuticals Inc. for approximately $930 million. This acquisition strengthens Alcon's ophthalmic pharmaceutical portfolio by adding innovative treatments such as Rocklatan and Rhopressa. Aerie Pharmaceuticals, based in the United States, specializes in developing treatments for eye diseases, including acute ocular pain.

Major players in the acute ocular pain market are AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Vision LLC, Sun Pharmaceutical Industries Ltd., Bausch + Lomb Corporation, Santen Pharmaceutical, Dompe Farmaceutici S.p.A., Aldeyra Therapeutics Inc., Ocular Therapeutix, Nicox S.A., Omeros Corporation, Chromocell Therapeutics Corporation, XOMA Corporation, Vyluma, Sylentis, Surface Ophthalmics Inc., Pharmaleads, Kala Bio, IACTA Pharmaceuticals.

Asia-Pacific was the largest region in the acute ocular pain market in 2024. North America expected to be the fastest-growing region in the forecast period. The regions covered in acute ocular pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute ocular pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute ocular pain market consists of sales of anesthetic eye drops, ocular antihistamines, neuroprotective agents, and combination ophthalmic formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Ocular Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute ocular pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute ocular pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute ocular pain market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Topical Non-Steroidal Anti-Inflammatory Drugs; Topical Cycloplegic Agents; Oral Analgesics; Corticosteroids; Immunomodulators
• 2) By Medical Condition: Corneal Abrasion; Glaucoma; Conjunctivitis; Iritis; Other Medical Conditions
• 3) By Route Of Administration: Topical; Intraocular; Oral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Ophthalmic Clinics; Other End Users
• Subsegments:
• 1) By Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ketorolac; Bromfenac; Nepafenac; Diclofenac
• 2) By Topical Cycloplegic Agents: Atropine; Cyclopentolate; Homatropine
• 3) By Oral Analgesics: Acetaminophen; Ibuprofen; Tramadol; Codeine
• 4) By Corticosteroids: Prednisolone; Dexamethasone; Fluorometholone; Loteprednol
• 5) By Immunomodulators: Cyclosporine; Tacrolimus; Lifitegrast
• Companies Mentioned: AbbVie Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Alcon Vision LLC; Sun Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Ocular Pain Market Characteristics

3. Acute Ocular Pain Market Trends And Strategies

4. Acute Ocular Pain Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Ocular Pain Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Ocular Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Ocular Pain Market Growth Rate Analysis
• 5.4. Global Acute Ocular Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Ocular Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Ocular Pain Total Addressable Market (TAM)

6. Acute Ocular Pain Market Segmentation

• 6.1. Global Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Non-Steroidal Anti-Inflammatory Drugs
• Topical Cycloplegic Agents
• Oral Analgesics
• Corticosteroids
• Immunomodulators
• 6.2. Global Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corneal Abrasion
• Glaucoma
• Conjunctivitis
• Iritis
• Other Medical Conditions
• 6.3. Global Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical
• Intraocular
• Oral
• Other Routes of Administration
• 6.4. Global Acute Ocular Pain Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Acute Ocular Pain Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Ophthalmic Clinics
• Other End Users
• 6.6. Global Acute Ocular Pain Market, Sub-Segmentation Of Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ketorolac
• Bromfenac
• Nepafenac
• Diclofenac
• 6.7. Global Acute Ocular Pain Market, Sub-Segmentation Of Topical Cycloplegic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atropine
• Cyclopentolate
• Homatropine
• 6.8. Global Acute Ocular Pain Market, Sub-Segmentation Of Oral Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acetaminophen
• Ibuprofen
• Tramadol
• Codeine
• 6.9. Global Acute Ocular Pain Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisolone
• Dexamethasone
• Fluorometholone
• Loteprednol
• 6.10. Global Acute Ocular Pain Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclosporine
• Tacrolimus
• Lifitegrast

7. Acute Ocular Pain Market Regional And Country Analysis

• 7.1. Global Acute Ocular Pain Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Ocular Pain Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Ocular Pain Market

• 8.1. Asia-Pacific Acute Ocular Pain Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Ocular Pain Market

• 9.1. China Acute Ocular Pain Market Overview
• 9.2. China Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Ocular Pain Market

• 10.1. India Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Ocular Pain Market

• 11.1. Japan Acute Ocular Pain Market Overview
• 11.2. Japan Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Ocular Pain Market

• 12.1. Australia Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Ocular Pain Market

• 13.1. Indonesia Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Ocular Pain Market

• 14.1. South Korea Acute Ocular Pain Market Overview
• 14.2. South Korea Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Ocular Pain Market

• 15.1. Western Europe Acute Ocular Pain Market Overview
• 15.2. Western Europe Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Ocular Pain Market

• 16.1. UK Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Ocular Pain Market

• 17.1. Germany Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Ocular Pain Market

• 18.1. France Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Ocular Pain Market

• 19.1. Italy Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Ocular Pain Market

• 20.1. Spain Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Ocular Pain Market

• 21.1. Eastern Europe Acute Ocular Pain Market Overview
• 21.2. Eastern Europe Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Ocular Pain Market

• 22.1. Russia Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Ocular Pain Market

• 23.1. North America Acute Ocular Pain Market Overview
• 23.2. North America Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Ocular Pain Market

• 24.1. USA Acute Ocular Pain Market Overview
• 24.2. USA Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Ocular Pain Market

• 25.1. Canada Acute Ocular Pain Market Overview
• 25.2. Canada Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Ocular Pain Market

• 26.1. South America Acute Ocular Pain Market Overview
• 26.2. South America Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Ocular Pain Market

• 27.1. Brazil Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Ocular Pain Market

• 28.1. Middle East Acute Ocular Pain Market Overview
• 28.2. Middle East Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Ocular Pain Market

• 29.1. Africa Acute Ocular Pain Market Overview
• 29.2. Africa Acute Ocular Pain Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Ocular Pain Market, Segmentation By Medical Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Ocular Pain Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Ocular Pain Market Competitive Landscape And Company Profiles

• 30.1. Acute Ocular Pain Market Competitive Landscape
• 30.2. Acute Ocular Pain Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Alcon Vision LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Ocular Pain Market Other Major And Innovative Companies

• 31.1. Bausch + Lomb Corporation
• 31.2. Santen Pharmaceutical
• 31.3. Dompe Farmaceutici S.p.A.
• 31.4. Aldeyra Therapeutics Inc.
• 31.5. Ocular Therapeutix
• 31.6. Nicox S.A.
• 31.7. Omeros Corporation
• 31.8. Chromocell Therapeutics Corporation
• 31.9. XOMA Corporation
• 31.10. Vyluma
• 31.11. Sylentis
• 31.12. Surface Ophthalmics Inc.
• 31.13. Pharmaleads
• 31.14. Kala Bio
• 31.15. IACTA Pharmaceuticals

32. Global Acute Ocular Pain Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Ocular Pain Market

34. Recent Developments In The Acute Ocular Pain Market

35. Acute Ocular Pain Market High Potential Countries, Segments and Strategies

• 35.1 Acute Ocular Pain Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Ocular Pain Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Ocular Pain Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer